BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting

Core Insights - BioXcel Therapeutics has completed an updated market opportunity assessment for IGALMI, indicating a larger than expected total addressable market for the treatment of acute agitation associated with bipolar disorders or schizophrenia in the at-home setting [1][2] - The assessment is based on the SERENITY At-Home clinical study and aims to inform the company's launch planning activities for IGALMI [1][3] Market Opportunity Assessment - The assessment involved interviews with 15 prescribers and 5 payers, along with survey responses from 180 prescribers, to gauge interest and potential market size for IGALMI [2] - Approximately 2.3 million treated bipolar disorder and schizophrenia patients in the U.S. experience frequent episodes of acute agitation at home, with up to 1.8 million potentially eligible for IGALMI treatment [5] - This translates to an estimated 86 million addressable annual episodes requiring treatment, a significant increase from previous estimates of 57-77 million [5] Prescriber and Payer Insights - Prescribers reported a moderate to high unmet need for at-home treatment options, noting that current treatments may be sedating or controlled substances [5] - There is strong prescriber interest in IGALMI, with expectations that it could be used in approximately 70% of their patients with schizophrenia and bipolar disorder [5] - Payers anticipate broad formulary coverage for IGALMI, indicating positive feedback on potential inclusion in treatment plans [5] Patient Demand and Advocacy - Patient interviews highlighted a high unmet need for effective at-home treatment options for acute agitation, reinforcing the urgency for IGALMI's availability [6] - Prior research indicated that patients with schizophrenia and bipolar disorder expect to use IGALMI in about 80% of their acute agitation episodes [5] Company Background - BioXcel Therapeutics is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience [16] - The company is focused on re-innovating existing drugs and leveraging big data to identify new therapeutic indications [16]